Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long-term Results of Two Phase III Randomized Controlled Trials.
Tore K KvienPhilip Gerard ConaghanLaure GossecVibeke StrandMikkel ØstergaardDenis PoddubnyyNicole WilliamsBrian PorterAbhijit SheteIsabelle GilloteauAtul A DeodharPublished in: Arthritis care & research (2020)
Secukinumab provided rapid and sustained improvements in fatigue for up to 3 years, regardless of prior anti-TNF exposure.